BridgeBio Pharma (NASDAQ:BBIO) has entered
into a strategic collaboration with the University of Florida to
translate research in genetically driven disease towards clinical
development and potential commercialization.
BridgeBio will provide sponsorship to select
research programs around diseases with a genetic basis, including gene
therapies and large and small molecules and will provide guidance for
sponsored programs.
The company may conduct proof-of-concept studies for lead therapeutic compounds in relevant mammalian models.
Additionally, BBIO will also collaborate with Johns Hopkins University in the same indication.
https://seekingalpha.com/news/3584090-bridgebio-pharma-teams-up-university-of-florida-in-genetic-diseases
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.